
|Videos|March 29, 2021
Examining the Role of Frontline BTKi Monotherapy in CLL
Author(s)Jennifer R. Brown, MD, PhD
Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5






































